SAN DIEGO--(BUSINESS WIRE)--Jan. 11, 2006--AVANIR Pharmaceuticals (AMEX:AVN) announced today that it has signed an exclusive agreement with a leading importer and distributor of pharmaceuticals in Japan to develop and market AVANIR’s docosanol 10% cream (docosanol) as a treatment for cold sores in Japan. “Under the terms of the agreement, our Japanese partner will be responsible for all expenses incurred obtaining marketing approval, as well as the manufacture, distribution and promotion of the product in the territory. The agreement provides for AVANIR to receive a license fee, development and sales milestones, and a royalty on all product gross sales,” said Marty Emanuele, Ph.D., Vice President of Business Development and Licensing at AVANIR. “We look forward to a long and productive partnership.”
